Broadridge Financial Solutions BR
Technology · Information Technology Services · Synthos Deep Dive · 2026-07-03
The Overview
Broadridge is a behind-the-scenes plumbing company for Wall Street. When you own a stock or mutual fund, someone has to mail (or email) you the proxy vote, the annual report, and the tax forms, and someone has to process the trades banks make — Broadridge is that someone, for most of the industry. It gets paid steady, recurring fees to do boring, essential work that's very hard to switch away from.
The business is doing fine — sales and profits keep grinding higher every year, and it earns a very high return on the money shareholders put in. But the stock got cut almost in half over the past year, from about $272 down to $144. Nothing catastrophic happened to the company; the market simply decided it had paid too high a price and marked it down. That's why it now looks reasonably cheap relative to how much it earns.
Our verdict is Buy — Tactical: a decent-value buy in a solid, dull, cash-generating company — but "tactical," not "core," because (1) no outside experts we track are on record championing it, and (2) a stock in a clear downtrend can keep falling before it turns.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe). Steady recurring revenue, a calm stock that doesn't swing with the market, and manageable debt — but it's already fallen a lot, which shows sentiment can turn against it.
- Growth Quality 6/10 (solid, not spectacular). It grows reliably in the high-single digits and is very profitable, but it's not a fast grower.
- Exponential Potential 3/10 (low). This is a mature, utility-like company. Don't expect it to multiply several times over — expect slow, steady compounding.
The one big worry: the market may keep re-pricing a slow-and-steady grower downward, so even a cheap-looking, well-run company can stay cheap or get cheaper for a while.
Putting a number on it: our fair-value estimate is $187 against a current price of $183.64 — real upside if our numbers are right.
Our summary metrics
Low beta (0.90), sticky recurring revenue, modest 1.6× net-debt/EBITDA — but a −46% drawdown shows a re-rating already underway.
High-single-digit recurring-revenue growth, low-teens EPS CAGR, 40% ROE, but revenue growth is steady-not-accelerating.
A mature ~$17B compounder in a slow-growth utility-like niche; tokenization/AI optionality is real but small vs the base.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A mature ~$17B compounder in a slow-growth utility-like niche; tokenization/AI optionality is real but small vs the base.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $210 (high $257 / low $165; 15 Buy · 9 Hold · 0 Sell) — context, not our anchor |
| Valuation | 15.3× trailing EPS · ~15× FY26E · 14× FY27E · 10× FY30E · EV/S 2.7× · EV/EBITDA 10.0× |
| Technicals | Downtrend — $143.95, −46% off 52-wk high, below 50/200-DMA, RSI 49, −41% 12-mo (SPY +21%) |
| Conviction | Low breadth — 0 expert voices, 0 KB claims. This is a quant/fundamental call, stated plainly. |
| Position sizing | Satellite value/quality, ~1.5–3%, scaled in — the falling knife has not clearly bottomed |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for BR — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $183.64, 17% above the 50-day average ($157), 3% above the 200-day average ($178) — an uptrend. 29% below the 52-week high of $257, 36% above the 52-week low of $135.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $183.64 is currently inside the band (band $158–$189).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 69.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.48, positive momentum.
Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago
Solid = BR · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Broadridge Financial Solutions (NYSE: BR) is a ~$17B-market-cap financial-technology and communications company spun out of ADP in 2007, headquartered in Lake Success, NY, with ~14,000 employees. Its fiscal year ends June 30. It operates the essential, largely invisible infrastructure of the securities industry across two reportable segments:
- Investor Communication Solutions (ICS) — processes and distributes proxy materials, regulatory disclosures, tax documents, and shareholder communications; runs the ProxyEdge electronic voting system and the Broadridge Communications Cloud. This is the crown-jewel "governance" franchise: Broadridge handles a dominant share of US shareholder proxy distribution and voting.
- Global Technology & Operations (GTO) — end-to-end trade processing (order-to-settlement) across equities, fixed income, funds, FX and derivatives, plus wealth- and capital-markets technology, portfolio management, reconciliation, and outsourced operations.
Revenue mix (FY2025, from filings):
- By type (segmentation FMP reports): Recurring Fee Revenue $4.51B (65%) · Distribution Revenue $2.06B (30%) · Event-Driven Revenue $0.32B (5%). Recurring fee revenue is the value driver; distribution is low-margin pass-through postage/print; event-driven (mutual-fund proxy, corporate actions) is lumpy.
- By geography: United States $5.91B (~86%) · United Kingdom $0.46B · Canada $0.46B. The base is heavily US, and a small number of large financial-institution clients drive a large share of revenue (a concentration flagged in the company's own risk factors — see §11).
The strategic story management is pushing (§9): democratize/digitize governance, modernize wealth management, and lean into tokenization (it powered the first on-chain US public-company proxy vote and processes $354B/day on a distributed-ledger repo platform) and AI (agentic AI driving ~25% efficiency gains in its managed services).
2. The expert thesis (traceable)
There is no expert coverage for BR in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top claims array is empty. No independent voice we track — bullish or bearish — is on record on this name.
Per the Synthos house standard, that fact is stated plainly rather than papered over: this verdict carries no conviction-track weight. Everything below is derived from the fundamentals (FMP financials), analyst consensus estimates (labeled as estimates), and management's own guidance (half-weighted, §9). Readers should treat this as a quant/fundamental note, not an expert-panel note. Where a name like Eli Lilly earns a High conviction rating from 13 reconciled voices, BR earns none — and we will not manufacture one.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Below-average risk | Beta 0.90, sticky recurring revenue, net-debt/EBITDA 1.6×, interest coverage 11×, investment-grade (rating A-). Offsetting: a −46% drawdown proves sentiment can re-rate it hard, and it's still below both moving averages. |
| Growth Quality | 6 · Solid | ~7% recurring-revenue growth (constant currency), ~10–12% adjusted-EPS growth guided, 40% ROE, 13% ROIC, 31% gross / 27% EBITDA margins. High quality, but the growth rate itself is only moderate and not accelerating. |
| Exponential Potential | 3 · Low | A mature ~$17B processor in a slow-growth, utility-like niche. Revenue growth is steady in the mid-to-high single digits with a negative second derivative vs the post-COVID years. Tokenization/AI optionality is real but tiny vs the base. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. (EPS below are FMP consensus estimates, labeled as estimates.)
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Recurring growth reaccelerates toward 8%+, closed sales convert, tokenization/AI adds a visible new revenue leg; the market re-rates BR back toward its historical ~20× on FY27E EPS ~$10.40 → sentiment normalizes. | ~$240 (+67%) |
| Base (our anchor) | Guidance roughly holds — FY27E adjusted EPS ~$10.40, high-single-digit recurring growth; a durable low-teens compounder with 40% ROE earns a de-rated but fair ~18×. | ~$187 (+30%) |
| Bear | Recurring growth slips toward ~5%, event-driven softens, buybacks slow; the market keeps treating it as a low-growth utility and holds the multiple near today's ~12× on FY27E EPS. | ~$120 (−17%) |
Synthos fair value = the base case, ~$187 (+30%), with the full $120–$240 span as the honest range. Our base sits below the Street's $210 consensus (we apply a more conservative post-de-rating multiple) and our bear is below the Street's $165 low (we take the "utility, not growth" re-rating risk seriously). This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). BR is a quality compounder with low exponential potential:
- Forward growth: revenue CAGR FY25→FY30E ~5.1% ($6.89B → ~$8.84B consensus); EPS CAGR FY25→FY30E ~11% ($7.17 GAAP FY25 → ~$13.80 consensus FY30E) as buybacks and margin mix lift EPS above revenue growth. Solid, not explosive.
- Acceleration (the 2nd derivative) is flat-to-negative: revenue grew +7.4% (FY23), +7.4% (FY24), +5.9% (FY25); consensus has it around +7.8% (FY26E) then decelerating toward ~4–5% by FY29–30E. This is steady-state compounding, not an inflection.
- Room to run: the total addressable market (governance digitization, wealth-tech, capital-markets processing) is large, but Broadridge already holds dominant share in its core proxy franchise, so incremental TAM capture is incremental, not step-change. At ~$17B market cap, a 5× would imply ~$85B — implausible for a mid-single-digit-revenue-growth processor.
- Optionality: tokenization (first on-chain US proxy vote; $354B/day on its DLT repo platform, +392% YoY) and agentic AI (25% efficiency gains internally) are genuine and could add a new leg — but today they are rounding errors against a $6.9B base. Watch them; don't underwrite them.
Exponential Potential: Low (3/10). Own BR for durable ~10% EPS compounding + dividend + buyback at a de-rated price, not for a fast multibagger. A small, accelerating name with these returns would score 8–9; BR's maturity and decelerating top line cap it at 3.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $6.89B, +5.9% (FY24 $6.51B, +7.4% on FY23 $6.06B). Steady mid-single-digit growth; recurring fee revenue (the quality core) $4.51B, +6.8%.
- Quarterly trajectory (FY26 to date): Q1 $1.59B → Q2 $1.71B → Q3 $1.95B (+8% YoY; recurring revenue +7% cc). Q4 is seasonally the largest (proxy season) — Street models ~$2.17B.
- Margins: gross 31.3% TTM, EBITDA 27.1% TTM, operating 17.1% TTM, net 15.0% TTM. (Note the "cost of revenue" includes low-margin distribution pass-through, which optically depresses gross margin; the recurring-fee business is far more profitable.) Adjusted operating margin runs ~20%+.
- Earnings: net income $839.5M FY25 (+20% on FY24's $698M); GAAP EPS $7.17 (diluted $7.10). Adjusted EPS is higher and is what management guides on (FY26 adjusted-EPS growth guided 10–12%).
- Cash flow: operating CF $1.17B, capex −$115M (asset-light, capex only ~1% of revenue), FCF $1.06B FY25 (+12% YoY); FCF yield ~7.8% on EV. Clean, high-conversion cash generation.
- Returns on capital: ROE 40.1%, ROIC 13.4%, ROCE 18.3% — genuinely elite capital efficiency, partly flattered by leverage and buybacks (tangible book is negative, a function of goodwill from acquisitions).
- Balance sheet: total debt $3.46B, net debt $2.90B, net-debt/EBITDA ~1.6×, interest coverage ~11×. Investment-grade, easily serviceable. Current ratio 0.94 (normal for a fee processor with deferred revenue).
6. Valuation — priced in or room?
After the ~46% drawdown, BR is no longer expensive: 15.3× trailing GAAP EPS, ~15× FY26E, 14× FY27E, ~10× FY30E, EV/sales 2.7×, EV/EBITDA 10.0×, FCF yield ~7.8%, dividend yield ~2.7% (payout ~39%). For a business with 40% ROE, ~90%+ recurring/visible revenue, and low-teens EPS growth, that is a below-historical multiple — BR spent much of the last decade at 20–28× earnings. The bear's rebuttal is that the de-rating is deserved: growth is only mid-single-digit on the top line, and the market may permanently reclassify it from "compounder" to "financial utility," holding the multiple near 12–15×.
Our base case applies a ~18× multiple to FY27E EPS ~$10.40 → ~$187 (+30%) — a partial, not full, re-rating. Street targets (context): consensus $210, high $257, low $165 — our $187 base is more conservative than consensus because we don't assume a full return to the old multiple. Not a deep-value screamer, but a reasonable price for durable quality — a quality-compounder-at-a-discount buy rather than a growth buy.
7. Technicals (from the tech block)
- Trend: down. $143.95 sits below the 50-DMA ($148.3) and far below the 200-DMA ($192.4), and the 50 is below the 200 (death-cross posture). MACD −3.08 (negative). This is a clear downtrend, not a base.
- Location: −46% off the 52-week high ($266.89), only +6.3% off the 52-week low ($135.44) — near the lows, deep drawdown (max −46% from peak). The knife has not demonstrably stopped falling.
- Momentum: RSI(14) 49 — neutral, neither oversold nor overbought; no washout-bottom signal yet.
- Relative strength (the tell): BR −41.2% 12-mo vs SPY +20.6% and QQQ +30.3%; −10% 3-mo vs SPY +14%. Severe, persistent underperformance of both the market and the Nasdaq.
- Read: technicals do not confirm the fundamental value case — they warn it. A cheap stock in a death-cross downtrend can get cheaper. This argues strongly for scaling in and waiting for a momentum turn (price reclaiming the 50-DMA, MACD crossing positive) rather than a lump-sum entry.
8. Moat & competitive position
Broadridge's moat is entrenchment through mission-critical, high-switching-cost infrastructure. In investor communications it is effectively the industry utility for US shareholder proxy distribution and voting — a regulated, network-effect position that is extraordinarily hard to displace because it sits between issuers, brokers, and millions of investors. In trade processing (GTO), multi-year contracts, deep systems integration, and the operational risk of switching a settlement engine create very sticky, recurring, high-retention revenue (retention historically ~98%+). The asset-light model (capex ~1% of revenue) and 40% ROE reflect that moat.
The limits: it's a mature, share-dominant position, so growth comes from digitization, cross-sell, position growth (equity/fund account growth), and M&A rather than a wide-open TAM. Threats are secular (long-run shift away from paper/distribution revenue — though management is converting this to higher-margin digital) and client-concentration (a handful of large banks/brokers).
Peer set (market cap, from FMP — an imperfect IT-Services comp group, not pure-play analogs): Jabil $35.8B, Teledyne $30.2B, Zoom $25.6B, HP Inc. $20.1B, Wipro $19.8B, CDW $17.0B, Flex $50.1B, CGI $14.4B, Leidos $13.7B, Gartner $9.1B. None is a true proxy/securities-processing comp; Broadridge's closest real peers (SS&C, DTCC-adjacent processors) aren't in this list. Judge BR on its own recurring-revenue economics rather than this group.
9. Management, capital allocation & guidance
- Capital allocation: balanced and shareholder-friendly — a growing dividend (yield ~2.7%, payout ~39%), share repurchases ($135M FY25), and bolt-on M&A (e.g., the CQG acquisition expanding futures/options, and a $193M net acquisition spend in FY25), funded by ~$1.06B FCF. Debt is used moderately (net-debt/EBITDA 1.6×). This is textbook mature-compounder capital allocation.
- Insider activity: the recent filings (2026-06 window) are routine — director stock awards and a CFO RSU vesting with an in-kind tax withholding (F-InKind at $137.93). No open-market cluster selling or buying that signals a view. Neutral.
- Management's own guidance (the earnings-call track, half-weighted — they talk their own book): the FY26 Q3 earnings presentation (SEC 8-K, filed 2026-04-30) is a genuine earnings release with explicit guidance. Management raised FY26 guidance: Recurring revenue growth (constant currency) to "at or above 7%" and Adjusted EPS growth to 10–12%. Q3 highlights they cite: recurring revenue +7% cc, adjusted EPS +11% to $2.72, Governance revenue $800M (+8%), Wealth/Investment Mgmt $193M (+8%), Capital Markets $295M (flat, on a 7-pt prior-year license headwind), $58M closed sales in the quarter ($147M YTD), and strategic emphasis on tokenization ($354B/day on its DLT repo platform, +392% YoY) and AI ($800B+ assets on an AI-native voting engine; 25% managed-services efficiency gains). Treat these as management's self-interested framing — but the numbers reconcile to the reported financials and support the low-teens-EPS-growth base case.
10. Catalysts & what to watch
- Next earnings: 2026-08-04 (FY26 Q4 — the seasonally largest, proxy-season quarter; Street EPS $3.76, revenue ~$2.17B). The key lines: recurring-revenue growth (constant currency), closed sales / sales backlog, and initial FY27 guidance.
- Closed sales conversion: $147M YTD closed sales is the forward-revenue pipeline — watch the annual total and its conversion to recurring revenue.
- Tokenization / DLT traction: whether the on-chain governance and DLT repo volumes ($354B/day) start showing up as revenue, not just activity.
- AI efficiency → margin: whether the 25% managed-services efficiency gains translate into adjusted-operating-margin expansion.
- Multiple re-rating: a reclaim of the 50-/200-DMA and a positive MACD cross would be the technical confirmation that the de-rating has run its course.
Thesis tripwires (what would change the call): recurring-revenue growth slipping below ~5% cc; FY27 guidance for adjusted-EPS growth below high-single-digits; a break to new lows below ~$135 on heavy volume; or FCF conversion deteriorating.
11. Key risks
- Sentiment / de-rating not over (the immediate risk): BR is in a clear downtrend (−46% from high, below both MAs, death cross). A cheap-looking, slowly-growing stock can keep de-rating if the market fixes it as a "utility, not growth" multiple.
- Client concentration (structural, company-flagged): Broadridge's own risk factors cite "reliance on a relatively small number of clients" and continued use "with favorable pricing terms." Loss of, or pricing pressure from, a large bank/broker client would hurt.
- Secular distribution decline: the low-margin distribution/print revenue is in long-run structural decline; the digital transition is a partial offset, not a guarantee.
- Cyclicality of activity-based revenue: trade volumes, event-driven (mutual-fund proxy, corporate actions), and position growth flex with market activity and participation — a securities-market slowdown pressures the activity-linked portion.
- Growth is only moderate: even the bull case is low-teens EPS growth — there is no exponential upside to bail out a multiple mistake.
- No expert corroboration: unlike our conviction-track names, no tracked analyst voice supports (or challenges) this thesis; the call rests entirely on the numbers.
12. Verdict, position sizing & monitoring
Buy — Tactical. Broadridge is a high-quality, entrenched financial-infrastructure compounder — 40% ROE, ~$1.06B FCF, sticky recurring revenue, management guiding 10–12% adjusted-EPS growth — that has been marked down ~46% into a genuinely reasonable ~15× forward multiple. The fundamentals support a base-case fair value of ~$187 (+30%). But this is Tactical, not Core, for two honest reasons: (1) there is zero expert coverage in our KB — no conviction-track corroboration, so the call is purely quant/fundamental; and (2) the technicals are in a downtrend (death cross, near 52-week lows), so the market is still repricing it and a value trap is possible.
- Sizing: satellite, ~1.5–3%, explicitly scaled in — a starter now, adds on a momentum turn (reclaim of the 50-DMA / positive MACD) or a fundamental confirmation at the 2026-08-04 print. Do not lump-sum into a falling knife.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score at each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $143.95.
- Single biggest risk: the re-rating isn't finished — a steady 10–12% grower can keep de-rating if the market permanently reclassifies it as a low-multiple utility.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage for BR in the Synthos knowledge base. This is disclosed prominently (§2); the verdict is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and none is claimed here.
- Data as-of: fundamentals 2026-03-31 (FY26 Q3) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: FY26 guidance (recurring-revenue growth "at or above 7%," adjusted-EPS growth 10–12%) is management's own book, half-weighted by design; sourced from the SEC 8-K earnings release filed 2026-04-30.
- Peer caveat: the FMP peer list is a generic IT-Services group and contains no true securities-processing analog; used only for scale context.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").